Navigation Links
Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Date:2/20/2008

Conference Call and Webcast to Follow

THE WOODLANDS, Texas, Feb. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its fourth quarter and year end 2007 financial results on Thursday, March 6, 2008 after the financial markets close. Lexicon management will hold a conference call to discuss its clinical development progress, financial results for 2007 and financial guidance for 2008 at 5:00 p.m. Eastern Time on March 6, 2008.

The dial-in number for the conference call is 877-681-3378 (within the United States) or 719-325-4842 (international). The pass code for all callers is 7721341. Investors can access a live webcast of the call at http://www.lexpharma.com. An archived version of the webcast will be available on the website through March 11, 2008.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon a
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
2. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
4. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
5. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
6. Lexicon Pharmaceuticals to Present at Bio InvestorForum
7. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
8. Lexicon Appoints Judith Swain, M.D. to Board of Directors
9. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Leaders of Milwaukee, Racine, and Waukesha counties signed an ... expansion of the Center for Advanced Technology and ... is intended to increase the number of high-paying technology ... in order to keep area innovations in technology from ...
... Morgan Stanley in the Ronald Perelman case is a clarion ... First, a quick recap of the main points in the ... sued by billionaire financier Ronald Perelman , Morgan Stanley could ... in the case ruled that Morgan Stanley deliberately violated her ...
... Madison, Wis. - Governor Jim Doyle announced Friday ... Wisconsin. , ,The Consortium on Biobased Industry, ... private sectors, will work with the State Departments of ... Office to determine what the state government can do ...
Cached Biology Technology:Southeastern Wisconsin Technology Collaboration 2Southeastern Wisconsin Technology Collaboration 3Southeastern Wisconsin Technology Collaboration 4$1.45 billion judgment against Morgan Stanley sends message revisit e-mail retention policies 2$1.45 billion judgment against Morgan Stanley sends message revisit e-mail retention policies 3Doyle announces biobased energy consortium 2Doyle announces biobased energy consortium 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... chloride ions are critical to hearing in mammals, which builds ... off boats might disrupt the balance of these ions in ... show that chloride ions are crucial for our exquisite sense ... Surgery and Neurobiology and first author of the study in ...
... and harvest gardens of fungus have a secret ... antibiotic-producing bacteria that the insects harbor on their ... an international team led by University of Wisconsin-Madison ... nature of this mutualistic relationship. The researchers ...
... beaches hit Rhode Island's Narragansett Bay during the summer ... which literally suffocates sea life. While some evidence of ... surface, Brown University ecologists went underwater and discovered a ... mussel reefs located in the central bay, researchers found ...
Cached Biology News:Study reveals classic symbiotic relationship between ants, bacteria 2Study reveals classic symbiotic relationship between ants, bacteria 3'Dead zone' summer killed billions of ocean state mussels 2
...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... 178-227 of human YBX2. (Note: ... proprietary). ...
... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
... General description: Aminopropylsilane is ... used slide chemistry for ... Coated Slides for Microarrays ... glass substrate for printing ...
Biology Products: